Pfizer has received approval from the US Food and Drug Administration (FDA) for Geodon capsules as part of a combination maintenance treatment for bipolar disorder in adults.
The FDA has approved Geodon for the treatment of bipolar 1 disorder as an adjunct to lithium or valproate in adults.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Bipolar disorder affects about 5.7 million adults in the US and needs lifelong treatment and management.
Geodon is also FDA-approved for the treatment of acute manic and mixed episodes associated with bipolar disorder, with or without psychotic features, and for the treatment of schizophrenia.
